These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35477935)

  • 1. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
    Kneller DW; Li H; Phillips G; Weiss KL; Zhang Q; Arnould MA; Jonsson CB; Surendranathan S; Parvathareddy J; Blakeley MP; Coates L; Louis JM; Bonnesen PV; Kovalevsky A
    Nat Commun; 2022 Apr; 13(1):2268. PubMed ID: 35477935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity.
    Kneller D; Li H; Phillips G; Weiss K; Zhang Q; Arnould M; Jonsson C; Surendranathan S; Parvathareddy J; Blakeley M; Coates L; Louis J; Bonnesen P; Kovalevsky A
    Res Sq; 2022 Feb; ():. PubMed ID: 35169792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.
    Citarella A; Dimasi A; Moi D; Passarella D; Scala A; Piperno A; Micale N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
    Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J
    J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Poli ANR; Tietjen I; Nandwana NK; Cassel J; Messick TE; Register ET; Keeney F; Rajaiah R; Verma AK; Pandey K; Acharya A; Byrareddy SN; Montaner LJ; Salvino JM
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0056224. PubMed ID: 39225484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease.
    Macchiagodena M; Pagliai M; Procacci P
    J Mol Graph Model; 2022 Jan; 110():108042. PubMed ID: 34653812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.
    Zhao Y; Fang C; Zhang Q; Zhang R; Zhao X; Duan Y; Wang H; Zhu Y; Feng L; Zhao J; Shao M; Yang X; Zhang L; Peng C; Yang K; Ma D; Rao Z; Yang H
    Protein Cell; 2022 Sep; 13(9):689-693. PubMed ID: 34687004
    [No Abstract]   [Full Text] [Related]  

  • 11. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.
    Bai Y; Ye F; Feng Y; Liao H; Song H; Qi J; Gao GF; Tan W; Fu L; Shi Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):51. PubMed ID: 33542181
    [No Abstract]   [Full Text] [Related]  

  • 12. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
    Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 M
    Qiao J; Li YS; Zeng R; Liu FL; Luo RH; Huang C; Wang YF; Zhang J; Quan B; Shen C; Mao X; Liu X; Sun W; Yang W; Ni X; Wang K; Xu L; Duan ZL; Zou QC; Zhang HL; Qu W; Long YH; Li MH; Yang RC; Liu X; You J; Zhou Y; Yao R; Li WP; Liu JM; Chen P; Liu Y; Lin GF; Yang X; Zou J; Li L; Hu Y; Lu GW; Li WM; Wei YQ; Zheng YT; Lei J; Yang S
    Science; 2021 Mar; 371(6536):1374-1378. PubMed ID: 33602867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
    Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
    J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paxlovid: Mechanism of Action, Synthesis, and
    Marzi M; Vakil MK; Bahmanyar M; Zarenezhad E
    Biomed Res Int; 2022; 2022():7341493. PubMed ID: 35845944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332.
    Pavan M; Bolcato G; Bassani D; Sturlese M; Moro S
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1646-1650. PubMed ID: 34289752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors.
    Kim H; Hauner D; Laureanti JA; Agustin K; Raugei S; Kumar N
    Sci Rep; 2022 Dec; 12(1):21037. PubMed ID: 36470873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.